The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.
AffiliationCancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 9BX, United Kingdom.
MetadataShow full item record
AbstractAnti-Epstein-Barr Virus (EBV) vaccines are being developed which are based on the gp340/220 membrane antigen (MA) gene products from the B95-8 strain. Some proteins are known to be immunologically quite different between type-A (1) and type-B (2) strains of EBV and therefore from a vaccine point of view it was critical to evaluate the degree of conservation of gp340/220. The complete MA coding sequence was determined for two B-type viruses, AG876 and P3HR-1, for comparison with the A-type B95-8. A variable region within MA was sequenced from several other strains. In addition the other open reading frames within the MA-containing BamHI-L fragment of AG876 were sequenced and compared. The results show that there is a high degree of homology between all strains examined. Although some differences were found within the MA coding sequence the only major site of variation was within the repeat region and no consistent A/B changes were found. Monoclonal antibodies generated against A-type MA and representing six epitope groups along the length of the gp340 molecule were found to recognize B-type gp340, thereby demonstrating functional homology. We conclude that, as a vaccine antigen, B95-8 gp340/220 should be equally effective against both types of EBV.
CitationThe Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. 1993, 195 (2):578-86 Virology
- Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.
- Authors: Mackett M, Cox C, Pepper SD, Lees JF, Naylor BA, Wedderburn N, Arrand JR
- Issue date: 1996 Nov
- Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.
- Authors: Pither RJ, Zhang CX, Shiels C, Tarlton J, Finerty S, Morgan AJ
- Issue date: 1992 Feb
- Cloning and analysis of the Epstein-Barr virus glycoprotein 350 genes.
- Authors: Chang SH, Kim SH, Lee WK, Kim HJ, Choi SH, Park JH, Jang HS, Chung GH, Kwon TH, Kim DH, Yang MS, Jang YS
- Issue date: 1998 Oct 31
- Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
- Authors: Wallace LE, Wright J, Ulaeto DO, Morgan AJ, Rickinson AB
- Issue date: 1991 Jul
- Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.
- Authors: Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E
- Issue date: 1990 Sep